Tumor-derived exosome component (TDE component)

Tumor-derived exosomes are small extracellular vesicles, typically 30–150 nm in diameter, secreted by tumor cells into the local microenvironment and circulation. These exosomes carry a diverse range of surface proteins (such as tetraspanins, integrins, adhesion molecules, PD-L1, MHC molecules) and nucleic acids (miRNAs, mRNAs, lncRNAs, and occasionally DNA). They function as mediators of cell communication, modulating processes including immune evasion, angiogenesis, tumor cell invasion, metastasis, reprogramming of stromal and immune cells, and drug resistance. The heterogeneity of their cargo reflects the high diversity of tumor biology, making tumor-derived exosomal proteins and nucleic acids both promising biomarkers for cancer detection and monitoring as well as experimental targets for therapy. However, “tumor-derived exosome surface proteins/nucleic acids” is not a single molecular target, but a collective designation for functionally relevant exosomal components exported from tumor cells

Other names

Tumor-derived extracellular vesicle proteinTumor exosome proteinTumor-derived exosomal nucleic acidTDE cargoOncosome protein or nucleic acid

For inhibitors: Block exosome biogenesis/secretion (e.g., via ESCRT or sphingomyelinase pathway inhibition) For antibodies or immunotherapies: Blockade of tumor-promoting proteins (e.g., anti-PD-L1) Molecular cargo delivery inhibitors